Evaluation of experimental therapeutics in a new mouse model of Helicobacter felis utilizing 16S rRNA polymerase chain reaction for detection.
BACKGROUND
A new mouse model of Helicobacter felis infection, which mimics the human infection observed with H. pylori, has recently been developed utilizing polymerase chain reaction (PCR) based on the 16S rRNA gene sequence for detection of infection.


METHODS
We tested several therapeutic regimens in this model, including some currently utilized in the clinic and some shown ineffective in the clinic.


RESULTS
The therapeutic results obtained by PCR with this model are consistent with results observed in the published human H. pylori clinical trials and also with results obtained in another H. felis mouse model utilizing culture and histology.


CONCLUSIONS
These results support further use of this new model in screening for new therapeutic regimens for the management of Helicobacter disease.
Smith
J G
JG
Antibiotic Discovery and Development, Merck Research Laboratories, Merck and Co., Inc., Rahway, New Jersey 07065-0900, USA.
Kong
L
L
Abruzzo
G K
GK
Gill
C J
CJ
Flattery
A M
AM
Scott
P M
PM
Silver
L
L
Kropp
H
H
Bartizal
K
K
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D016998:Helicobacter; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D051379:Mice; D009853:Omeprazole / Q000008:administration & dosage / Q000627:therapeutic use; D016133:Polymerase Chain Reaction; D012336:RNA, Ribosomal, 16S
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D012336:RNA, Ribosomal, 16S; D009853:Omeprazole